Press releases - Vicore Pharma

2022-05-11 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

2022-05-05 | Regulatory

Interim report January - March 2022

Gothenburg, May 5, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2022. Read more

2022-04-21

Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)

2022-04-07 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2022-04-07 | Regulatory

Vicore Pharma publishes the Annual Report for 2021

Gothenburg, April 7, 2022 –Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (ATRAGs), today… Read more

2022-03-23 | Regulatory

Michael Wolff Jensen resigns from the Vicore board of directors and is replaced by Jacob Gunterberg as chairman of the board up until the annual general meeting in May 2022

Gothenburg, March 23, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (ATRAGs),… Read more

2022-03-18

Vicore initiates human forearm blood flow study with C21

· Forearm blood flow is a technique to measure vasodilation and blood flow in man · If successful, this will allow a faster and more… Read more

2022-03-09

Vicore strengthens rare lung disease pipeline with PAH indication

· Strong preclinical data shows that C21 reverses vascular remodelling · Proof-of-concept trial in pulmonary arterial hypertension ("PAH") planned to start late 2022 · Appointment… Read more

2022-03-04

Vicore to host R&D Day

Thursday, March 10 at 15-17 CET (9-11 AM EST) Gothenburg, Sweden, March 4, 2022 – Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company… Read more

2022-02-25 | Regulatory

Year-end report 2021

Gothenburg, February 25, 2022 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2021. Read more

2022-02-23

Vicore takes major step towards a clinical platform company targeting AT2R – new molecule ready for phase 1

· The new AT2R agonist C106, with patent protection to 2041, is ready to enter a phase 1 trial · Four additional AT2R agonists are… Read more

2022-02-10 | Regulatory

Vicore’s AIR study interim analysis suggests that C21 improves lung function in IPF patients

· FVC increased by an average +251 ml over baseline at 24 weeks · Between 24 and 36 weeks, FVC was either stable or continued… Read more

2021-11-04 | Regulatory

Interim report July - September 2021

Gothenburg, November 4, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2021. Read more

2021-11-02 | Regulatory

Vicore’s C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study

· The results showed nearly 50% reduction in lung injury in the C21 group compared with the placebo group · These positive findings together with… Read more

2021-10-25

Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19

· The trial showed that C21 reduced the need for supplemental oxygen and mechanical ventilation, indicating faster patient recovery. C21 was also found to be… Read more

2021-10-20 | Regulatory

Vicore announces the Nomination Committee for the 2022 Annual General Meeting

Gothenburg, October 20, 2021 – Vicore Pharma Holding AB (publ) has appointed the Nomination Committee for the 2022 Annual General Meeting. The three largest shareholders… Read more

2021-09-22

Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)

Webinar on Thursday, September 30 @ 16:00 CET (10AM ET) with the medical doctors and IPF experts Prof. Toby Maher and Prof. Joanna Porter. Gothenburg,… Read more

2021-09-22

Vicore obtains SARS coronavirus patent for C21 in the USA

Gothenburg, September 22, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces… Read more

2021-09-17

Vicore starts dosing of first COVID-19 patients in the global phase 3 trial ATTRACT-3

Gothenburg, September 17, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today announces… Read more

2021-08-27

Vicore strengthens its management team

Gothenburg, August 27, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as… Read more

2021-08-26 | Regulatory

Interim report April - June 2021

Gothenburg, August 26, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2021. Read more

2021-06-15

Vicore announces participation in investor meetings during June 2021

Gothenburg, June 15, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as… Read more

2021-06-11

Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19

Gothenburg, June 11, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as… Read more

2021-05-11 | Regulatory

Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)

2021-05-05 | Regulatory

Interim report January - March 2021

Gothenburg, May 5, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2021. Read more

2021-05-04 | Regulatory

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF

· Webinar will be held today at 15:00 CET (9:00 am EST) · Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program Gothenburg,… Read more

2021-04-20

Vicore Pharma to host Key Opinion Leader webinar on C21 for the treatment of COVID-19

KOL webinar being held on Wednesday, April 28[th] @ 14:00 CET (8 am EST) Gothenburg, April 20, 2021 – Vicore Pharma Holding AB (publ) (“Vicore”),… Read more

2021-04-15 | Regulatory

Vicore Pharma publishes the Annual Report for 2020

Gothenburg, April 15, 2021 – Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis… Read more

2021-04-08 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2021-03-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

Gothenburg, March 31, 2021– Vicore Pharma Holding AB (publ)’s registered share capital and number of outstanding shares and votes have increased during the month of… Read more

2021-03-11 | Regulatory

Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Gothenburg, March 11, 2021 – Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis… Read more

2021-03-05 | Regulatory

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ)

2021-02-26 | Regulatory

Increase of number of shares and votes in Vicore Pharma

Gothenburg, February 26, 2021– Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”, or the “Company”) registered share capital and number of outstanding shares and votes have… Read more

2021-02-26 | Regulatory

Year-end report 2020

Gothenburg, February 26, 2021 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2020. Read more

2021-02-09 | Regulatory

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Gothenburg, are summoned to the extraordinary general meeting Friday 5… Read more

2021-02-09 | Regulatory

Vicore Pharma has completed a directed share issue of SEK 336 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN,… Read more

2021-02-09 | Regulatory

Vicore Pharma intends to carry out a directed share issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN,… Read more

2021-02-01

Positive data from Phase II study ATTRACT in patients with COVID-19 published online

Gothenburg, February 1, 2021 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today published data… Read more

2020-12-21 | Regulatory

Positive results show that C21 can become an important complement to COVID-19 vaccines

Gothenburg, December 21, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today reports an… Read more

2020-12-15

Vicore Pharma announces Last Patient Last Visit in the mechanistic phase II study with C21 in systemic sclerosis

Gothenburg, December 15, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for serious lung disorders, today announces that… Read more

2020-12-08 | Regulatory

Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19

Oral C21 treatment demonstrates significant clinical improvement on top of corticosteroids Gothenburg, December 08, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated… Read more

2020-11-16

Vicore Pharma recruits the first patient in the phase II Proof-of-Concept study in idiopathic pulmonary fibrosis

Gothenburg, November 16, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that… Read more

2020-11-06 | Regulatory

Interim report July-September 2020

Gothenburg, November 6, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2020. Read more

2020-11-03 | Regulatory

Vicore announces changes in management team

Gothenburg, November 3, 2020 - Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces changes… Read more

2020-11-02 | Regulatory

Vicore strengthens its pipeline with the acquisition of novel AT2R agonists and decides on an issue in kind of 142,054 shares

Gothenburg, November 2, 2020 – Vicore Pharma Holding AB (publ) (“Vicore”), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces… Read more

2020-10-06 | Regulatory

Vicore Pharma announces the Nomination Committee for the 2021 Annual General Meeting

Gothenburg, October 6, 2020 – Vicore Pharma Holding AB (publ) has appointed the Nomination Committee for the 2021 Annual General Meeting. The three largest shareholders… Read more

2020-10-01

Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial

Gothenburg, October 1, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that… Read more

2020-09-25

Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue

Gothenburg, September 25, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces effects… Read more

2020-08-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

Gothenburg, August 31, 2020 – Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”, or the “Company”) registered share capital and number of outstanding shares and votes… Read more

2020-08-26 | Regulatory

Interim report April-June 2020

Gothenburg, August 26, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2020. Read more

2020-08-25

Vicore Pharma restarts mechanistic study with VP01 in systemic sclerosis

Gothenburg, August 25, 2020 – Vicore Pharma Holding (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that patients… Read more

2020-08-13 | Regulatory

Vicore Pharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED… Read more

2020-07-27

Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India

Gothenburg, July 27, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that… Read more

2020-07-02 | Regulatory

Vicore Pharma has completed a directed share issue of SEK 185 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED… Read more

2020-07-02 | Regulatory

Vicore Pharma intends to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, , CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE… Read more

2020-06-23

Vicore Pharma expands recruitment base for the ATTRACT study

Gothenburg, June 23, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that… Read more

2020-06-22

Vicore Pharma's drug candidate VP01 demonstrates potential for significant benefit in severe pulmonary hypertension

Gothenburg, June 22, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, announces positive results… Read more

2020-05-29

LifeArc awards £ 1.5 million grant to Vicore Pharma for the VP01 COVID-19 clinical study

Gothenburg, May 29, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that… Read more

2020-05-20 | Regulatory

Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)

2020-05-05 | Regulatory

Interim report January - March 2020

Gothenburg, May 5, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2020. Read more

2020-05-05

Vicore Pharma receives regulatory approval to start phase II clinical trial with VP01 (C21) in patients with IPF

Gothenburg, May 5, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the… Read more

2020-05-04

Vicore offers advance voting in connection with the 2020 AGM

Gothenburg, May 4, 2020 – Vicore Pharma Holding AB (publ) hereby informs that the shareholders may exercise their voting rights at the Annual General Meeting… Read more

2020-04-28

Vicore Pharma gets regulatory approval to start phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection

Gothenburg, April 28, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the… Read more

2020-04-17 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2020-04-15 | Regulatory

Vicore Pharma publishes the Annual Report for 2019

Gothenburg, April 15, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announced the… Read more

2020-03-31 | Regulatory

Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection

Gothenburg, March 31, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the submission of a… Read more

2020-03-30

Vicore submits clinical trial application for phase II trial with C21 in IPF

Gothenburg, March 30, 2020 – Vicore Pharma, a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces submission of the clinical… Read more

2020-03-20

Vicore informs on clinical programs in relation to the current outbreak of COVID-19

Gothenburg, March 20, 2020 – Vicore Pharma informs on clinical programs in relation to the current outbreak of COVID-19. Read more

2020-02-28 | Regulatory

Year-end report 2019

Gothenburg, February 28 2020 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2019. Read more

2020-01-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

Gothenburg, January 31, 2020 – Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”) registered share capital and number of outstanding shares and votes have increased during… Read more

2019-12-18

Update on progress for drug development programs VP01 (C21) and VP02 (IMiD)

Gothenburg, December 18, 2019 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces an… Read more

2019-11-29 | Regulatory

Increase of number of shares and votes in Vicore Pharma

Gothenburg, November 29, 2019 – Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”, or the “Company”) registered share capital and number of outstanding shares and votes… Read more

2019-11-13 | Regulatory

Vicore Pharma has completed a directed share issue of approximately SEK 125 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, THE UNITED KINGDOM, CANADA, HONGKONG, JAPAN, SWITZERLAND, NEW ZEALAND, SINGAPORE, SOUTH AFRICA,… Read more

2019-11-12 | Regulatory

Vicore Pharma intends to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, THE UNITED KINGDOM, CANADA, HONGKONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, THE… Read more

2019-11-08 | Regulatory

Interim report January-September 2019

Gothenburg, November 8, 2019 - Vicore Pharma Holding AB (publ) publish the interim report for the third quarter 2019. Read more

2019-10-03 | Regulatory

Vicore Pharma announces the Nomination Committee for the 2020 Annual General Meeting

Gothenburg, October 3, 2019 – Vicore Pharma Holding AB (publ) has appointed the Nomination Committee for the 2020 Annual General Meeting. The three largest shareholders… Read more

2019-10-01

Update on progress in clinical lead program VP01 (C21)

Gothenburg, October 1, 2019 – Following the successful dose escalation phase I study, Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative… Read more

2019-09-16 | Regulatory

Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Gothenburg,September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) (”Vicore” or the “Company”) announced that Nasdaq Stockholm’s listing committee had approved that the Company’s… Read more

2019-09-11 | Regulatory

Vicore Pharma has been approved for listing on Nasdaq Stockholm

Gothenburg, September 11, 2019 – Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding AB (publ)’s (”Vicore”) application to be listed on Nasdaq Stockholm’s main… Read more

2019-09-06 | Regulatory

Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study

2019-08-23 | Regulatory

Interim report April-June 2019

Mölndal, August 23, 2019 – Vicore Pharma Holding (publ) publish the interim report for the second quarter 2019. Read more

2019-05-15 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) (”Vicore Pharma”) on 15 May 2019. Read more

2019-05-15 | Regulatory

Interim report January - March 2019

Mölndal, May 15, 2019 – Vicore Pharma Holding (publ) publishes the interim report for the first quarter 2018. Read more

2019-04-23 | Regulatory

Vicore Pharma announces systemic sclerosis as the second indication for VP01

Mölndal, April 23, 2019 - Vicore Pharma AB (publ) a leading rare diseases pharmaceutical company today announces that it has selected diffuse systemic sclerosis (dSSc)… Read more

2019-04-12 | Regulatory

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Mölndal, are summoned to the Annual General Meeting on Wednesday… Read more

2019-04-12 | Regulatory

Vicore Pharma's Annual Report 2018 published

Mölndal, April 12, 2019 - Vicore Pharma Holding AB (publ) announces today that the annual report for 2018 has been published and is available on… Read more

2019-03-15 | Regulatory

Year-end report 2018

Mölndal, March 15, 2019 – Vicore Pharma Holding (publ) (ticker: VICO) publish the year-end report for 2018 Read more

2019-02-13

Vicore Pharma postpones publication of year-end report

Mölndal, February 13, 2019 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the year-end report for 2018. The year-end report… Read more

2019-01-07 | Regulatory

Press release from the extraordinary general meeting of Vicore Pharma

2018-11-30 | Regulatory

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

The shareholders in Vicore Pharma Holding AB (publ), reg. no. 556680-3804 (the “Company”), are hereby summoned to attend an Extraordinary General Meeting (“EGM”) on Monday… Read more

2018-11-30 | Regulatory

Vicore Pharma’s Board of Directors has resolved on a directed share issue of around SEK 160 million to finance the continued development of the drug development programs VP01 and VP02

NOT FOR DISTRIBUTION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UK, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN… Read more

2018-11-08 | Regulatory